Cyclosporin H boosts a new lentivirus-delivered gene therapy with enhanced anti-sickling properties in blood stem cells from ...

Vyriad, Inc., a clinical-stage biotechnology company developing the next generation of targeted genetic therapies, today announced a strategic collaboration with Novartis to discover and develop in ...

The latent HIV reservoir is a major barrier to HIV cure. Combining latency reversal agents (LRAs) with differing mechanisms of action such as AZD5582, a non-canonical NF-kB activator, and I-BET151, a ...

OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical ...

Vyriad, Rochester’s growing drug development company, signed a “huge” collaboration deal with Novartis to drive its genetic ...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) shared encouraging updates on its Danon Disease Program through a recent investor ...

This approach aims to restore the production of a functional protein ... Additionally, Spirovant Sciences is working on a CF ...

To develop the next generation of in vivo T cell therapy, Novartis will leverage Vyriad's active targeting lentiviral vector ...

Here, we used deep full-length single-cell RNA-sequencing to distinguish post-mitotic cone and rod developmental states and cone-specific features that contribute to retinoblastomagenesis. The ...

Challenge studies including Poulvac ® Procerta ® HVT-IBD showed early onset of immunity against classical and variant IBDV at ...